Kaken Pharmaceutical Co., Ltd. (KKPCF) Stock

About Kaken Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd., a Tokyo-based company established in 1917, operates globally, specializing in the development, manufacture, and commercialization of a diverse array of medical products, medical devices, and agrochemicals. Its comprehensive portfolio spans various therapeutic areas. Key pharmaceutical offerings include Clenafin, a topical solution for onychomycosis; Artz, an anti-osteoarthritis medication; Seprafilm, an absorbable adhesion barrier used on damaged tissue; Fiblast, a spray designed for treating pressure and other skin ulcers; Regroth, a product aiding periodontal regeneration; and Hernicore, used for lumbar disc herniation. Other notable pharmaceutical products include Adofeed and Loxoprofen Na Tape, both pain- and inflammation-relieving plasters; Ebrantil, addressing dysuria and hypertension; Procylin, an oral prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Ropion, an injectable pain reliever. Beyond human medicine, Kaken supplies a range of agrochemicals and animal health solutions. These include Polyoxins, a fungicide; Pentoxazone, a herbicide for rice; and Salinomycin, an anti-coccidial feed additive for poultry. The company also maintains an active research and development pipeline. Promising candidates currently under development include BBI-4000, which has completed Phase III trials for primary axillary hyperhidrosis; KMW-1, also in Phase III for the removal of eschar from thermal burns; KAR, aimed at treating hide lice infestation; and KP-607, presently in Phase II for onychomycosis. Interestingly, its operations also extend to real estate, with involvement in the rental management of Bunkyo Green Court, a commercial complex. Its products are marketed under well-known brands such as Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia. Strategic partnerships include license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC.

Kaken Pharmaceutical Co., Ltd. is headquartered in JP.

Kaken Pharmaceutical Co., Ltd. (KKPCF) stock trades at $26.00 with a market capitalization of $984.58M. The stock is valued at a price-to-earnings (P/E) ratio of 68.50, price-to-book of 0.99, price-to-sales of 1.91. Over the past 52 weeks the stock has ranged between $22.30 and $28.12, and currently trades 7.5% below its 52-week high. It pays a dividend yielding 4.50%.

On profitability, Kaken Pharmaceutical Co., Ltd. generates a return on equity (ROE) of 1.46%, return on capital employed of -0.57%, an operating margin of -1.17%, a net profit margin of 2.79%.

Official website: www.kaken.co.jp